Bonker
10 Feb 2017
Q1 2017 blog update - ETX Q1 2017 blog weekly ETX chart update - notes under each chart:[link]
Bonker
06 Feb 2017
ETX chart [link]
nk1999
22 Mar 2016
Results RNS available at company's website. although seems to be missing in III newsfeed?[link] prioritisation on discovery platform and commercialisation 22 March 2016: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces its full year results for the year ended 31 January 2016.Operational highlights· Highly productive discovery platform - Strategic focus for the business, now fully developed and generating many potent compounds- 12 active projects (FY15: 6) and three projects in lead optimisation (FY15: nil)· ETS6103 - detailed update on analysis of Phase IIb trial results- Confirmed antidepressant activity for SSRI non-responders - Fewer side effects and better tolerance profile than current post-SSRI treatment· ETS2101 - refocus from infused form to explore oral form- Early phase experimental clinical trials completed- New data suggests potential for compound when given without a steroid pre-med · Board changes - appointment of Professor Trevor Jones as Non-Executive Director and Iain Ross as Non-Executive Chairman · Prioritisation of asset commercialisation - progressing more projects from discovery platform and seeking partners for assets Financial highlights · Net cash at £24.8m (FY15: £33.8m)· Operating loss of £11.6m (FY15: loss of £10.2m) · R&D tax credit of £2.5m (FY15: £2.0m)· Discovery spend was £4.3m (FY15: £2.7m) due to the increase in number of active projectsProfessor Malcolm Young, CEO of e-Therapeutics, said: "This has been a very productive year for our discovery platform which continues to exceed our expectations by generating high quality, potent compounds. Some of these programmes have the potential to be game changers in immuno-oncology, cancer drug-resistance and anti-infection. "Detailed analysis of the Phase IIb clinical data for ETS6103 has confirmed its effectiveness as an anti-depressant for patients who have not responded to an SSRI. Early stage exploratory clinical trials on ETS2101 have established an acceptable dose for this product candidate and important information concerning the potential route of administration. "Our main priorities are to drive the productivity of the discovery platform further and realise shareholder value through the commercialisation of our assets. We maintain a healthy cash position in support of our strategy."
nk1999
26 Feb 2015
Re: Good news but why? RNS out today afternoon. Good operational progress. Not sure if that warrants a steep rise in SP as seen over the last few days, including a further 15% today.But I have not heard of any takeover rumor or anything else. May be there is something going on?nk
Actinidia
26 Feb 2015
Re: Good news but why? Clearly somebody knows something we don't. Would that be called insider trading I wonder.
JoshuaLeung
26 Feb 2015
Good news but why? I have held these for three years and am finally in profit but no idea why! - any news?
